These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . 805-395-9669 Pipeline, Stories of Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). We will now confidently further focus our capital resources on development and commercialization of our pipeline of first-in-kind therapeutics for severe diseases.. The 90,000 sq. INVESTORS & MEDIA: FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies, will operate the new site. achapman@atarabio.com, View this news release online at: Atara Biotherapeutics Announces the Completion of the Acquisition of Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. Suite 102 FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Atara Biotherapeutics Strengthens Board; Senior Management Team 914-789-8523, Photofinishing & Personalized Photo Products. About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Atara believes that its cash as of December 31, 2021, together with the anticipated $100.0 million payable to Atara upon closing of the strategic transaction with FDB, will be sufficient to fund . Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Potential application for a wide range of disease-causing viral and non-viral targets. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. ehyllengren@atarabio.com Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). It will be operated as part of FUJIFILM Diosynth Biotechnologies' global network . ehyllengren@atarabio.com The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy . in fighting diseaseto develop transformative therapies for patients with cancer and autoimmune conditions. We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Sclerosis, Clinical Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. An archived replay will be available on the Company's website for 30 days. Global Multicancer Screening Market to Reach $7.78 Billion by 2032 Atara Biotherapeutics Announces $31 Million Royalty Interest Financing SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. The parties will also enter a long-term supply agreement, which could extend to ten years. "Global Multicancer Screening Market to Reach $7.78 Billion by 2032." Industry Overview. FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. The ability to identify and leverage synergies between its businesses is a key strength of Fujifilm and fundamental to its growth strategy. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Its lead product includes Tab-cel (tabelecleucel), a T-cell . Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. With our lead program in Phase 3 clinical development . Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. Strength, Multiple Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more. Sign up today for your free Reader Account. Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. reserved. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. Information for Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Alex Chapman Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. (Business Wire) Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. We're harnessing the natural biology of T cellsour bodys most effective weapon About FUJIFILM Corporation FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. Despite also reporting a financial loss for the quarter, Atara's shares climbed nearly 24% Tuesday morning to . As part of the agreement, FUJIFILM Diosynth Biotechnologies and Atara will enter into a long-term manufacturing and services agreement, which could extend to ten years to support the production of Ataras clinical pipeline, which includes tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. FUJIFILM Corporation has invested over USD 5.5 billion to grow the Bio CDMO business unit in order to provide our customers with long-term support across a full-range of modalities, and manufacturing scales, said Takatoshi Ishikawa, senior executive vice president, general manager Bio CDMO Division, FUJIFILM Corporation. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. FUJIFILM Holdings America Corporation. Media Atara Biotherapeutics, Inc. . Atara Biotherapeutics Announces $31 Million Royalty Interest Financing

Laurel Edwards Illness 2021, St Michael Orland Park Bulletin, Articles A